KR100695846B1 - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR100695846B1
KR100695846B1 KR1020037010870A KR20037010870A KR100695846B1 KR 100695846 B1 KR100695846 B1 KR 100695846B1 KR 1020037010870 A KR1020037010870 A KR 1020037010870A KR 20037010870 A KR20037010870 A KR 20037010870A KR 100695846 B1 KR100695846 B1 KR 100695846B1
Authority
KR
South Korea
Prior art keywords
administered
compound
compounds
rapamycin
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037010870A
Other languages
English (en)
Korean (ko)
Other versions
KR100695846B9 (ko
KR20040007451A (ko
Inventor
하이디 라네
테렌스 오라일리
지네트 마조리 우드
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100695846(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040007451A publication Critical patent/KR20040007451A/ko
Application granted granted Critical
Publication of KR100695846B1 publication Critical patent/KR100695846B1/ko
Publication of KR100695846B9 publication Critical patent/KR100695846B9/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
KR1020037010870A 2001-02-19 2002-02-18 암 치료 Expired - Lifetime KR100695846B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0104072.4 2001-02-19
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
GB0124957.2 2001-10-17
PCT/EP2002/001714 WO2002066019A2 (en) 2001-02-19 2002-02-18 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057017585A Division KR20050095906A (ko) 2001-02-19 2002-02-18 암 치료

Publications (3)

Publication Number Publication Date
KR20040007451A KR20040007451A (ko) 2004-01-24
KR100695846B1 true KR100695846B1 (ko) 2007-03-19
KR100695846B9 KR100695846B9 (ko) 2021-09-30

Family

ID=26245731

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020037010870A Expired - Lifetime KR100695846B1 (ko) 2001-02-19 2002-02-18 암 치료
KR1020057017585A Ceased KR20050095906A (ko) 2001-02-19 2002-02-18 암 치료
KR1020077022986A Ceased KR20070102762A (ko) 2001-02-19 2002-02-18 암 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020057017585A Ceased KR20050095906A (ko) 2001-02-19 2002-02-18 암 치료
KR1020077022986A Ceased KR20070102762A (ko) 2001-02-19 2002-02-18 암 치료

Country Status (27)

Country Link
US (10) US8410131B2 (enExample)
EP (11) EP3342411B1 (enExample)
JP (14) JP2004525899A (enExample)
KR (3) KR100695846B1 (enExample)
CN (5) CN104116738A (enExample)
AU (1) AU2002250968C1 (enExample)
BR (1) BR0207378A (enExample)
CA (3) CA2860306C (enExample)
CY (11) CY1116616T1 (enExample)
CZ (5) CZ303611B6 (enExample)
DK (6) DK3342411T3 (enExample)
ES (8) ES2600304T3 (enExample)
HK (2) HK1250018B (enExample)
HU (1) HUP0303271A3 (enExample)
IL (13) IL157425A0 (enExample)
LT (9) LT3342411T (enExample)
LU (3) LU92880I2 (enExample)
MX (3) MX368013B (enExample)
NO (14) NO333105B1 (enExample)
NZ (1) NZ527692A (enExample)
PL (5) PL231418B1 (enExample)
PT (7) PT2269603E (enExample)
RU (8) RU2322981C2 (enExample)
SI (6) SI3351246T1 (enExample)
SK (5) SK288524B6 (enExample)
TW (2) TWI334350B (enExample)
WO (1) WO2002066019A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
BR0210101A (pt) * 2001-06-01 2004-06-08 Wyeth Corp Combinações antineoplásticas
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
HRP20060073B1 (hr) 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
EP2228452B1 (en) * 2004-02-23 2014-07-16 Novartis AG P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR20060130764A (ko) * 2004-03-23 2006-12-19 아스트라제네카 아베 병용 요법
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
EP2253320A1 (en) * 2005-07-20 2010-11-24 Novartis AG Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor
EP2662082A1 (en) 2005-11-14 2013-11-13 Ariad Pharmaceuticals, Incorporated Administration of mTOR inhibitors
AU2006314444C1 (en) * 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
CA2637255C (en) 2006-02-02 2018-06-12 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
CN101415409B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
WO2008027837A2 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
EP2190409B9 (en) * 2007-08-16 2019-03-06 Biocompatibles UK Limited Delivery of drug combinations
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US20120040896A1 (en) * 2008-04-11 2012-02-16 The Regents Of The University Of Colorado Compositions, methods and uses for modulation of brca 1
RU2509774C2 (ru) * 2008-08-04 2014-03-20 Файв Прайм Терапьютикс, Инк. Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
CA2874509C (en) 2012-05-23 2021-01-26 Smith & Nephew Plc Apparatuses and methods for negative pressure wound therapy
EP4112020B1 (en) 2012-08-01 2025-12-10 Smith & Nephew plc Wound dressing and method of treatment
CA3178997A1 (en) 2012-08-01 2014-02-06 Smith & Nephew Plc Wound dressing
JP6715598B2 (ja) 2013-03-15 2020-07-01 スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ 創傷ドレッシングおよび治療方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
JP6623745B2 (ja) * 2015-06-29 2019-12-25 富士通株式会社 電子回路及び発振器の制御方法
CN107787373B (zh) * 2015-08-17 2021-11-26 库拉肿瘤学公司 法尼基转移酶抑制剂在制备用于治疗癌症的药物中的用途
EP3429583A1 (en) * 2016-03-15 2019-01-23 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN110753532B (zh) 2017-06-30 2022-04-12 T.J.史密夫及内修有限公司 负压伤口治疗设备
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
CA3098692A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
WO2019212991A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
AU2019409366B2 (en) 2018-12-18 2022-10-27 Novartis Ag Rapamycin derivatives
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
EP4417205A4 (en) 2021-10-14 2025-10-22 Pharos Ibio Co Ltd COMPOSITION FOR COMBINATION THERAPY COMPRISING A 2,3,5-SUBSTITUTED THIOPHENE COMPOUND
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
AU5151093A (en) 1992-10-14 1994-05-09 Unichema Chemie Bv Process for the preparation of alkylglycosides
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
SG64372A1 (en) * 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
AU2356195A (en) * 1994-04-14 1995-11-10 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU712193B2 (en) * 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997047317A1 (en) * 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
WO1998009970A2 (en) 1996-09-09 1998-03-12 American Home Products Corporation Alkylated rapamycin derivatives
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9619631D0 (en) 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
AU749623B2 (en) 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
RU2203058C2 (ru) * 1998-04-27 2003-04-27 Фудзисава Фармасьютикал Ко., Лтд. Фармацевтическая композиция
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
PT1210350E (pt) 1999-08-18 2004-10-29 Wyeth Corp Esteres de sdz-rad soluveis em agua
AU2292801A (en) 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
AU2623201A (en) * 1999-12-30 2001-07-16 Kam W Leong Controlled delivery of therapeutic agents by insertable medical devices
AU2001230956B2 (en) 2000-01-14 2005-08-18 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
CN100448487C (zh) * 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
CA2425665C (en) 2000-10-31 2013-07-16 Cook Incorporated Coated implantable medical device
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
WO2002056790A2 (en) * 2000-12-22 2002-07-25 Avantec Vascular Corporation Delivery of therapeutic capable agents
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
PL363991A1 (en) 2001-04-06 2004-11-29 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
BR0210101A (pt) * 2001-06-01 2004-06-08 Wyeth Corp Combinações antineoplásticas
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
EP2726140B1 (en) 2011-07-01 2020-12-16 Coloplast A/S A catheter with a balloon
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Also Published As

Publication number Publication date
CZ2010473A3 (enExample) 2004-01-14
SK288545B6 (sk) 2018-03-05
CY1121983T1 (el) 2020-05-29
CY2016047I1 (el) 2017-04-05
JP6349474B2 (ja) 2018-06-27
JP6904640B2 (ja) 2021-07-21
IL229160B (en) 2018-08-30
RU2322981C2 (ru) 2008-04-27
EP3143995B2 (en) 2025-01-15
JP2018168188A (ja) 2018-11-01
JP6349475B2 (ja) 2018-06-27
NO336110B1 (no) 2015-05-18
IL157425A0 (en) 2004-03-28
EP2762140B1 (en) 2017-03-22
LU93320I2 (fr) 2017-01-30
JP2014177469A (ja) 2014-09-25
CY2019043I1 (el) 2020-05-29
EP2269603B1 (en) 2015-05-20
CZ2018211A3 (enExample) 2004-01-14
LTPA2020503I1 (lt) 2020-03-10
LU92880I2 (fr) 2016-11-17
PT3345602T (pt) 2022-07-04
NO20131545L (no) 2003-10-17
US20140105895A1 (en) 2014-04-17
JP2015145411A (ja) 2015-08-13
CY1116616T1 (el) 2017-03-15
RU2005105664A (ru) 2006-08-10
EP3351246B8 (en) 2019-09-18
TW200626151A (en) 2006-08-01
PL409579A1 (pl) 2015-03-02
NO343599B1 (no) 2019-04-08
CY1121314T1 (el) 2020-05-29
CN104116738A (zh) 2014-10-29
CA2860306C (en) 2018-04-17
SK288546B6 (sk) 2018-03-05
ES2744377T3 (es) 2020-02-24
NO335134B1 (no) 2014-09-22
NO340924B1 (no) 2017-07-17
IL229156A0 (en) 2013-12-31
HK1146245A1 (en) 2011-05-27
US20130244951A1 (en) 2013-09-19
CZ307940B6 (cs) 2019-09-04
CY1121715T1 (el) 2020-05-29
ES2543383T3 (es) 2015-08-18
IL202155A (en) 2013-04-30
JP2014193901A (ja) 2014-10-09
LT2269604T (lt) 2016-11-10
LTPA2019511I1 (lt) 2019-06-25
US20120214774A1 (en) 2012-08-23
LT2762140T (lt) 2017-06-26
SI3143995T1 (sl) 2019-02-28
CY2020005I1 (el) 2020-05-29
NO20150831A1 (no) 2015-06-24
NO20130045L (no) 2003-10-17
NO20190290A1 (no) 2003-10-17
US20120283285A1 (en) 2012-11-08
CZ200591A3 (cs) 2019-01-23
LT3143995T (lt) 2019-01-25
NZ527692A (en) 2005-05-27
RU2018121314A3 (enExample) 2021-10-06
CN1679559A (zh) 2005-10-12
CY2016047I2 (el) 2017-04-05
LT3351246T (lt) 2019-07-10
EP3345602A1 (en) 2018-07-11
IL157425A (en) 2013-10-31
ES2600304T3 (es) 2017-02-08
IL259724A (en) 2018-08-30
JP6383814B2 (ja) 2018-08-29
JP6349476B2 (ja) 2018-06-27
HK1250019A1 (en) 2018-11-23
JP2004525899A (ja) 2004-08-26
NO333105B1 (no) 2013-03-04
US20130287769A1 (en) 2013-10-31
PL363918A1 (pl) 2004-11-29
KR100695846B9 (ko) 2021-09-30
EP3143995B1 (en) 2018-12-05
NO20033651D0 (no) 2003-08-18
IL229158A (en) 2017-03-30
ES2921798T3 (es) 2022-08-31
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
US20040147541A1 (en) 2004-07-29
CN1551767A (zh) 2004-12-01
JP2018100282A (ja) 2018-06-28
SK288834B6 (sk) 2021-03-10
SI2269603T1 (sl) 2015-08-31
DK2269603T3 (en) 2015-08-24
CZ307637B6 (cs) 2019-01-23
PL231418B1 (pl) 2019-02-28
IL251270B (en) 2018-06-28
NO336581B1 (no) 2015-09-28
US20130296359A1 (en) 2013-11-07
CZ309178B6 (cs) 2022-04-20
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
CA2860306A1 (en) 2002-08-29
EP2764865A3 (en) 2014-10-01
ES2705016T3 (es) 2019-03-21
US8436010B2 (en) 2013-05-07
LUC00122I1 (enExample) 2019-06-06
EP2783686A8 (en) 2015-03-04
TWI334350B (en) 2010-12-11
IL220096A0 (en) 2012-07-31
DK3342411T3 (da) 2019-09-02
EP2269603A1 (en) 2011-01-05
IL229160A0 (en) 2013-12-31
IL259724B (en) 2021-12-01
IL229159A0 (en) 2013-12-31
JP5879391B2 (ja) 2016-03-08
EP1363627A2 (en) 2003-11-26
JP5873128B2 (ja) 2016-03-01
CA2438504C (en) 2016-02-16
CA2994779C (en) 2020-08-25
KR20040007451A (ko) 2004-01-24
NO20131544L (no) 2003-10-17
IL202155A0 (en) 2010-06-16
CA2438504A1 (en) 2002-08-29
PT3143995T (pt) 2019-01-17
PT3342411T (pt) 2019-09-19
EP3345602B1 (en) 2022-04-06
ES2728739T3 (es) 2019-10-28
JP2020143134A (ja) 2020-09-10
IL229157A0 (en) 2013-12-31
JP2012184238A (ja) 2012-09-27
HK1250018B (en) 2020-04-17
EP3342411B1 (en) 2019-08-21
IL220095A0 (en) 2012-07-31
NO20033651L (no) 2003-10-17
RU2011138835A (ru) 2013-03-27
US20160303092A1 (en) 2016-10-20
US20130253000A1 (en) 2013-09-26
SI2762140T1 (sl) 2017-07-31
CY1119029T1 (el) 2018-01-10
NO20131546L (no) 2003-10-17
CY2015044I2 (el) 2017-03-15
IL250676A0 (en) 2017-03-30
CZ309247B6 (cs) 2022-06-22
CN104083365A (zh) 2014-10-08
JP2016222705A (ja) 2016-12-28
RU2006140514A (ru) 2008-05-27
CY2019030I1 (el) 2020-05-29
EP3143995A1 (en) 2017-03-22
NO334646B1 (no) 2014-05-05
IL250676B (en) 2018-06-28
CN104274442A (zh) 2015-01-14
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
PL414997A1 (pl) 2016-02-29
NO336208B1 (no) 2015-06-15
EP3342411A1 (en) 2018-07-04
CA2994779A1 (en) 2002-08-29
MX2019010879A (es) 2019-12-16
LTC2269604I2 (lt) 2020-01-27
HK1198946A1 (en) 2015-06-19
NO20131547L (no) 2003-10-17
US20130059877A1 (en) 2013-03-07
SI3342411T1 (sl) 2019-10-30
NO336428B1 (no) 2015-08-17
ES2629317T3 (es) 2017-08-08
KR20070102762A (ko) 2007-10-19
DK3351246T3 (da) 2019-06-03
RU2018127821A (ru) 2020-01-30
SI3351246T1 (sl) 2019-08-30
JP6333766B2 (ja) 2018-05-30
NO20170803A1 (no) 2003-10-17
JP6310970B2 (ja) 2018-04-11
HK1250336B (en) 2020-02-07
PT3351246T (pt) 2019-06-07
RU2445093C2 (ru) 2012-03-20
SK10382003A3 (sk) 2004-03-02
WO2002066019A2 (en) 2002-08-29
WO2002066019A3 (en) 2002-10-24
SI2269604T1 (sl) 2016-11-30
JP2017081979A (ja) 2017-05-18
CZ20032209A3 (cs) 2004-01-14
RU2003127391A (ru) 2005-03-27
HUP0303271A3 (en) 2010-09-28
ES2640787T3 (es) 2017-11-06
IL251270A0 (en) 2017-06-29
LTPA2016035I1 (lt) 2016-12-27
JP2014208657A (ja) 2014-11-06
MX368013B (es) 2019-09-13
HK1146247A1 (en) 2011-05-27
EP2762140A1 (en) 2014-08-06
CN1296043C (zh) 2007-01-24
US8410131B2 (en) 2013-04-02
EP2269604A1 (en) 2011-01-05
EP3406249A1 (en) 2018-11-28
IL220096A (en) 2015-10-29
MXPA03007418A (es) 2003-11-18
CY1118316T1 (el) 2017-04-05
HUP0303271A2 (hu) 2004-01-28
RU2013143306A (ru) 2015-03-27
SK288524B6 (sk) 2018-01-04
RU2659725C2 (ru) 2018-07-03
CY2015044I1 (el) 2017-03-15
NO340553B1 (no) 2017-05-08
LUC00122I2 (enExample) 2019-12-24
SK902019A3 (enExample) 2004-03-02
KR20050095906A (ko) 2005-10-04
NO2015010I1 (no) 2015-03-30
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
CZ2019248A3 (cs) 2004-01-14
HK1197723A1 (en) 2015-02-13
JP2018100281A (ja) 2018-06-28
JP2007284454A (ja) 2007-11-01
PT2762140T (pt) 2017-07-04
LT3342411T (lt) 2019-09-25
RU2013119705A (ru) 2014-11-10
JP5775022B2 (ja) 2015-09-09
DK2762140T3 (en) 2017-07-10
PT2269604T (pt) 2016-11-04
NO20161348A1 (no) 2016-08-24
PL414996A1 (pl) 2016-02-29
NO20120451L (no) 2003-10-17
NO20150895L (no) 2003-10-17
IL229156A (en) 2017-02-28
BR0207378A (pt) 2004-06-15
NO20150413L (no) 2003-10-17
US8778962B2 (en) 2014-07-15
AU2002250968B2 (en) 2006-01-12
EP2764865A2 (en) 2014-08-13
US8877771B2 (en) 2014-11-04
IL229158A0 (en) 2013-12-31
DK3143995T3 (en) 2019-01-28
IL220095A (en) 2017-05-29
EP2269604B1 (en) 2016-07-27
CY2019030I2 (el) 2020-05-29
EP2783686A1 (en) 2014-10-01
EP2783686B1 (en) 2017-06-21
PT2269603E (pt) 2015-09-09
AU2002250968C1 (en) 2018-01-04
PL415000A1 (pl) 2016-02-29
DK2269604T3 (en) 2016-11-14
JP2018100283A (ja) 2018-06-28
SK288630B6 (sk) 2019-01-08
CZ303611B6 (cs) 2013-01-09

Similar Documents

Publication Publication Date Title
KR100695846B1 (ko) 암 치료
HK1250336A1 (en) Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
HK1250018A1 (en) Rapamycin derivative for treating pancreas cancer
AU2002250968A1 (en) Cancer treatment
AU2017276287B2 (en) Cancer treatment
AU2014202334C1 (en) Cancer treatment
HK1232469A1 (en) A rapamycin derivative for treating lung cancer
HK1232469A (en) A rapamycin derivative for treating lung cancer
HK1197644A (en) Cancer treatment
HK1250019B (en) Rapamycin derivative for treating solid tumours

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20030819

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030819

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050317

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20050920

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20051121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20060222

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20051121

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20061129

Appeal identifier: 2006101001602

Request date: 20060222

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20060222

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20060222

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050920

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20030819

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060222

Effective date: 20061129

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20061129

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20060222

Decision date: 20061129

Appeal identifier: 2006101001602

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20061219

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20061204

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070309

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070312

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100223

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110217

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20120221

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130221

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130221

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140220

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140220

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150224

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150224

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160218

Start annual number: 10

End annual number: 10

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20160330

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20070309

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20160330

Decision date: 20200128

Appeal identifier: 2016100000901

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Appeal kind category: Invalidation

Request date: 20160414

Decision date: 20200128

Appeal identifier: 2016100000956

Patent event date: 20160414

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20070309

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20160414

Decision date: 20190920

Appeal identifier: 2016100000949

FPAY Annual fee payment

Payment date: 20170302

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170302

Start annual number: 11

End annual number: 11

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20170908

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20070309

Comment text: Registration of Establishment

Decision date: 20210927

Request date: 20170908

Appeal identifier: 2017100002874

Appeal kind category: Confirmation of the scope of right_affirmative

PR1001 Payment of annual fee

Payment date: 20180228

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20190227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20190227

Start annual number: 13

End annual number: 13

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20190920

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2016100000949

Request date: 20160414

Appeal kind category: Invalidation

Decision date: 20190920

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100000956; TRIAL DECISION FOR INVALIDATION REQUESTED 20160414

Effective date: 20200128

Free format text: TRIAL NUMBER: 2016100000901; TRIAL DECISION FOR INVALIDATION REQUESTED 20160330

Effective date: 20200128

PJ1301 Trial decision

Appeal kind category: Invalidation

Request date: 20160414

Decision date: 20200128

Appeal identifier: 2016100000956

Patent event code: PJ13011S05D

Patent event date: 20200128

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20160330

Decision date: 20200128

Appeal identifier: 2016100000901

FPAY Annual fee payment

Payment date: 20200227

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20200227

Start annual number: 14

End annual number: 14

PJ2001 Appeal

Patent event date: 20200128

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Patent event date: 20061129

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Invalidation

Decision date: 20210819

Appeal identifier: 2020200003010

Request date: 20200327

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20200729

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2016100000956

Request date: 20160414

Appeal kind category: Invalidation

Decision date: 20200128

PR1001 Payment of annual fee

Payment date: 20210302

Start annual number: 15

End annual number: 15

J122 Written withdrawal of action (patent court)
PJ1202 Withdrawal of action (patent court)

Patent event code: PJ12021R01D

Patent event date: 20210908

Comment text: Written Withdrawal of Action

Decision date: 20210819

Request date: 20200327

Appeal identifier: 2020200003010

Appeal kind category: Invalidation

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20210927

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2017100002874

Request date: 20170908

Appeal kind category: Confirmation of the scope of right_affirmative

Decision date: 20210927

PG1701 Publication of correction

Publication date: 20210930

PC1801 Expiration of term